2026年6月最新影响因子数据已更新，欢迎查询使用。如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
| 热门AI工具： |
论文引言生成
New
AI 写作痕迹检测
Hot
学术改写降重
论文讨论生成
参考文献挖掘工具
审稿意见辅助撰写
|
查看更多AI工具 >> |
| 近期推荐： | 热 全流程投稿协助套餐服务 | 热 SCI论文AI润色+人工QC服务 | 热 Springer Nature特刊征稿 |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | JOURNAL OF CLINICAL ONCOLOGY J CLIN ONCOL （此期刊被最新的JCR期刊SCIE收录） LetPub评分 9.9
53人评分
我要评分
声誉 9.9 影响力 9.9 速度 9.1 | |||||||||||||||||||||
| 期刊ISSN | 0732-183X | 安装APP，查看期刊最新消息
| ||||||||||||||||||||
| E-ISSN | 1527-7755 | |||||||||||||||||||||
| 2025-2026最新IF （数据来源于网友提供） | 注册或登录后，查看IF | |||||||||||||||||||||
| 实时影响因子 | 截止2026年9月20日：30.85 | |||||||||||||||||||||
| 2025-2026自引率 | 1.7%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年IF （数据来源于网友提供） | 41.904数据由网友[等待runner]收集提供 | |||||||||||||||||||||
| h-index | 494 | |||||||||||||||||||||
| CiteScore （ 2026年6月最新版） |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | http://jco.ascopubs.org/ | |||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||
| 期刊投稿网址 | https://www.editorialmanager.com/JCO-ASCOPUBS | |||||||||||||||||||||
| 该期刊中国学者近期发文 - New | Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study Author: Zhao, Yuanyuan; Zhao, Hongyun; Wang, Qiming; Yang, Kunyu; Li, Yongsheng; Fu, Zhenming; Yang, Weihua; He, Zhiyong; Wang, Yongsheng; Ma, Yuxiang; Yang, Yunpeng; Fang, Wenfeng; Xiao, Sa; Zhu, Hai; Zhu, Yi; Zhang, Li; Huang, Yan Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 28, pp. 2670-2679. DOI: 10.1200/JCO-26-00243 Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma Author: Ruan, Dan-Yun; Wang, Feng-Hua; Zhou, Yujuan; Xiang, Yanqun; Lin, Jinguan; Liu, Lin; Liu, Ping; Tang, Linquan; Ma, Yuxiang; Hou, Tao; Chen, Qiuyan; Li, Zhi-Ming; Han, Fei; Qu, Song; Qiu, Sufang; Han, Chen; Ma, Hongzhi; Su, Fang; Gao, Jin; Guo, Ye; Wu, Zheng; Wu, Hai-Jun; Zhao, Yanqiu; Fang, Meiyu; Hu, Man; Wu, Yuan; Cui, Shuo; Li, Mengyun; Zhao, Qiong; Xu, Rui-Hua Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 28, pp. 2690-2699. DOI: 10.1200/JCO-26-00640 Reply to: Different Stage But Similar Survival in Hepatocellular Carcinoma: A Dilemma of Treatment Timing? Author: Jin, Zhi-Cheng; Zhong, Bin-Yan; Zhu, Hai-Dong; Teng, Gao-Jun Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 28, pp. 2749-2750. DOI: 10.1200/JCO-26-01336 Reply to: Different Stage But Similar Survival in Hepatocellular Carcinoma: A Dilemma of Treatment Timing? Author: Chan, Landon L.; Chan, Stephen L Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 28, pp. 2750-2751. DOI: 10.1200/JCO-26-01342 | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足JOURNAL OF CLINICAL ONCOLOGY的语言要求，还能让JOURNAL OF CLINICAL ONCOLOGY编辑和审稿人得到更好的审稿体验，让稿件最大限度地被JOURNAL OF CLINICAL ONCOLOGY编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | AMER SOC CLINICAL ONCOLOGY, 2318 MILL ROAD, STE 800, ALEXANDRIA, USA, VA, 22314 | |||||||||||||||||||||
| 出版商 | American Society of Clinical Oncology | |||||||||||||||||||||
| 涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Biweekly | |||||||||||||||||||||
| 出版年份 | 1983 | |||||||||||||||||||||
| 年文章数 | 308点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 40.43% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 97.08% | |||||||||||||||||||||
| WOS期刊JCR分区 （ 2025-2026年最新版） | 注册或登录后，查看WOS分区等级 | |||||||||||||||||||||
| 期刊分区表预警名单 | 2026年03月发布的新锐学术版：不在预警名单中 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||
  | ||||||||||||||||||||||
| 《新锐期刊分区表》 （ 2026年3月发布） | 点击查看期刊分区表趋势图
| |||||||||||||||||||||
| 期刊分区表 （ 2025年3月升级版） |
| |||||||||||||||||||||
| 期刊分区表 （ 2023年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0732-183X%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 平均2月 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 约20% | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在JOURNAL OF CLINICAL ONCOLOGY顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study Author: Zhao, Yuanyuan; Zhao, Hongyun; Wang, Qiming; Yang, Kunyu; Li, Yongsheng; Fu, Zhenming; Yang, Weihua; He, Zhiyong; Wang, Yongsheng; Ma, Yuxiang; Yang, Yunpeng; Fang, Wenfeng; Xiao, Sa; Zhu, Hai; Zhu, Yi; Zhang, Li; Huang, Yan Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 28, pp. 2670-2679. DOI: 10.1200/JCO-26-00243 PubMed DOI |
| 2. | Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma Author: Ruan, Dan-Yun; Wang, Feng-Hua; Zhou, Yujuan; Xiang, Yanqun; Lin, Jinguan; Liu, Lin; Liu, Ping; Tang, Linquan; Ma, Yuxiang; Hou, Tao; Chen, Qiuyan; Li, Zhi-Ming; Han, Fei; Qu, Song; Qiu, Sufang; Han, Chen; Ma, Hongzhi; Su, Fang; Gao, Jin; Guo, Ye; Wu, Zheng; Wu, Hai-Jun; Zhao, Yanqiu; Fang, Meiyu; Hu, Man; Wu, Yuan; Cui, Shuo; Li, Mengyun; Zhao, Qiong; Xu, Rui-Hua Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 28, pp. 2690-2699. DOI: 10.1200/JCO-26-00640 PubMed DOI |
| 3. | Reply to: Different Stage But Similar Survival in Hepatocellular Carcinoma: A Dilemma of Treatment Timing? Author: Jin, Zhi-Cheng; Zhong, Bin-Yan; Zhu, Hai-Dong; Teng, Gao-Jun Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 28, pp. 2749-2750. DOI: 10.1200/JCO-26-01336 PubMed DOI |
| 4. | Reply to: Different Stage But Similar Survival in Hepatocellular Carcinoma: A Dilemma of Treatment Timing? Author: Chan, Landon L.; Chan, Stephen L Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 28, pp. 2750-2751. DOI: 10.1200/JCO-26-01342 PubMed DOI |
| 5. | Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743 Author: Ma, Yanling; Yan, Fei; Deng, Jie; Sun, Jianhai Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 27, pp. 2649-2649. DOI: 10.1200/JCO-26-00668 PubMed DOI |
| 6. | Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression Author: Chen, Guang-Liang; Guo, Yanjing; Liu, Xin; Yang, Ya'nan; Sang, Youzhou; Lu, Xueguan; Sun, Si; Shi, Xiao; Zhang, Yan; Chen, Tong-Zhen; Qu, Ning; Wen, Duo; Niu, Xiao-Shuang; Dong, Shu; Wang, Yu; Wang, Yulong; Wang, Jiachen; Zhang, Lu; Hu, Chaosu; Ji, Qinghai; Ji, Dongmei Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 27, pp. 2614-2624. DOI: 10.1200/JCO-26-00671 PubMed DOI |
| 7. | Olaparib in Metastatic Breast Cancer: The Impact of Prior Cyclin-Dependent Kinase 4 and 6 Inhibitor Exposure on Efficacy Author: Yan, Jinyin; Xiong, Wei; Cai, Haifeng Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 26, pp. 2557-2558. DOI: 10.1200/JCO-26-00539 PubMed DOI |
| 8. | Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study) Author: Li, Ting; Zhou, Teng; Wang, Biyun; Tao, Zhonghua; Zhao, Mingchuan; Wang, Leiping; Jin, Juan; Zhao, Yannan; Gong, Chengcheng; Cao, Jun; Miao, Haotao; Peng, Wenxia; Wang, Jianfei; Jin, Min; Hu, Xichun; Zhang, Jian Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 26, pp. 2543-2553. DOI: 10.1200/JCO-25-02021 PubMed DOI |
| 9. | Beyond Average Grams: Aldehyde Dehydrogenase 2*2 and Alcohol-Induced Young-Onset Pancreatic Cancer Author: Yang, Qiyuan; Li, Yaling; Li, Jun Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 25, pp. 2460-2461. DOI: 10.1200/jco-26-00323 PubMed DOI |
| 10. | Total Neoadjuvant Therapy With Long-Course Radiotherapy Versus Chemoradiotherapy in High-Risk Locally Advanced Rectal Cancer (TNTCRT): A Multicenter, Randomized, Phase III Trial Author: Wang, Xin; Tang, Yuanling; Lu, Junyang; Meng, Wenjian; Liu, Ping; Zhou, Jitao; Wen, Feng; Ding, Peirong; Li, Jun; Wang, Biao; Guo, Qing; Qiu, Jian; Sun, Hao; Deng, Xiangbing; Shen, Yali; Zeng, Hanjiang; Jiang, Dan; Wang, Di; Li, Yunfeng; Xiao, Yi; Wang, Ziqiang Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 25, pp. 2409-2421. DOI: 10.1200/JCO-25-03110 PubMed DOI |
|
|
  | ||||||||||||||||
|
投稿状态统计： 我要评分： | ||||||||||||||||
| 投稿前担心稿件结构或语言不够规范？试试稿件自查工具，一键检测 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验：共117条 |
||||||||||||||||
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2026 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
投稿信 (Cover Letter) 模板
